ACADIA Pharmaceuticals
ACAD
S$29.09
Share price
-2.71%
Change (1 day)
15.53%
Change (1 year)
Categories
P/S ratio for ACADIA Pharmaceuticals (ACAD)
P/S ratio as of July 2025 (TTM): 3.80
According to ACADIA Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.95. At the end of 2025 the company had a P/S ratio of 2.86.
P/S ratio history for ACADIA Pharmaceuticals from 2004 to 2025
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2025 | 2.86 | -2.95% |
| 2024 | 2.94 | -58.39% |
| 2023 | 7.08 | 41.98% |
| 2022 | 4.98 | -35.69% |
| 2021 | 7.75 | -59.72% |
| 2020 | 19.2 | -1.79% |
| 2019 | 19.6 | 88.49% |
| 2018 | 10.4 | -65.29% |
| 2017 | 29.9 | -85.14% |
| 2016 | 202 | -99.66% |
| 2015 | > 1000 | 126.94% |
| 2014 | > 1000 | 1220.3% |
| 2013 | > 1000 | 2761.2% |
| 2012 | 69.5 | 151.89% |
| 2011 | 27.6 | 2361.7% |
| 2010 | 1.12 | -85.83% |
| 2009 | 7.91 | -62.42% |
| 2008 | 21.0 | -61.22% |
| 2007 | 54.3 | 67.72% |
| 2006 | 32.4 | 113.64% |
| 2005 | 15.1 | -38.86% |
| 2004 | 24.8 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Vanda Pharmaceuticals VNDA | 1.38 | -63.80% | 🇺🇸 USA |
 Pfizer PFE | 2.21 | -41.77% | 🇺🇸 USA |
 Eli Lilly LLY | 14.8 | 289.61% | 🇺🇸 USA |
 Johnson & Johnson JNJ | 4.48 | 17.93% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.03 | -46.58% | 🇺🇸 USA |
 Adamas Pharmaceuticals
ADMS | N/A | N/A | 🇺🇸 USA |